Westhampton Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.47M | Sell |
9,800
-34
| -0.3% | -$7.32K | 1.02% | 27 |
|
|
2026
Q1 | $2.14M | Hold |
9,834
| – | – | 1% | 29 |
|
|
2025
Q4 | $2.25M | Sell |
9,834
-100
| -1% | -$22.8K | 1.06% | 28 |
|
|
2025
Q3 | $2.3M | Sell |
9,934
-40
| -0.4% | -$8.15K | 1.12% | 26 |
|
|
2025
Q2 | $1.85M | Sell |
9,974
-200
| -2% | -$37.2K | 0.96% | 32 |
|
|
2025
Q1 | $2.13M | Hold |
10,174
| – | – | 1.16% | 25 |
|
|
2024
Q4 | $1.81M | Buy |
10,174
+1,365
| +15% | +$251K | 0.92% | 33 |
|
|
2024
Q3 | $1.74M | Hold |
8,809
| – | – | 0.88% | 39 |
|
|
2024
Q2 | $1.51M | Buy |
8,809
+1,000
| +13% | +$166K | 0.82% | 41 |
|
|
2024
Q1 | $1.42M | Sell |
7,809
-750
| -9% | -$129K | 0.78% | 47 |
|
|
2023
Q4 | $1.33M | Sell |
8,559
-1,735
| -17% | -$253K | 0.79% | 47 |
|
|
2023
Q3 | $1.53M | Sell |
10,294
-75
| -0.7% | -$11K | 0.99% | 36 |
|
|
2023
Q2 | $1.4M | Sell |
10,369
-65
| -0.6% | -$9.53K | 0.91% | 39 |
|
|
2023
Q1 | $1.66M | Buy |
10,434
+10
| +0.1% | +$1.53K | 1.07% | 29 |
|
|
2022
Q4 | $1.68M | Buy |
10,424
+135
| +1% | +$20.7K | 1.14% | 26 |
|
|
2022
Q3 | $1.38M | Buy |
10,289
+200
| +2% | +$28.7K | 1.04% | 30 |
|
|
2022
Q2 | $1.54M | Buy |
10,089
+40
| +0.4% | +$6.11K | 1.09% | 30 |
|
|
2022
Q1 | $1.63M | Buy |
10,049
+50
| +0.5% | +$7.26K | 1.05% | 31 |
|
|
2021
Q4 | $1.35M | Sell |
9,999
-870
| -8% | -$103K | 0.83% | 42 |
|
|
2021
Q3 | $1.17M | Buy |
10,869
+280
| +3% | +$32K | 0.8% | 43 |
|
|
2021
Q2 | $1.19M | Buy |
10,589
+450
| +4% | +$50.7K | 0.78% | 43 |
|
|
2021
Q1 | $1.1M | Buy |
10,139
+3,975
| +64% | +$425K | 0.76% | 42 |
|
|
2020
Q4 | $660K | Buy |
6,164
+215
| +4% | +$20.7K | 0.49% | 58 |
|
|
2020
Q3 | $521K | Buy |
5,949
+1,024
| +21% | +$96.4K | 0.43% | 64 |
|
|
2020
Q2 | $484K | Buy |
4,925
+655
| +15% | +$57.7K | 0.42% | 66 |
|
|
2020
Q1 | $325K | Buy |
4,270
+1,170
| +38% | +$99.7K | 0.34% | 73 |
|
|
2019
Q4 | $274K | Hold |
3,100
| – | – | 0.22% | 94 |
|
|
2019
Q3 | $235K | Sell |
3,100
-700
| -18% | -$48K | 0.2% | 99 |
|
|
2019
Q2 | $276K | Buy |
+3,800
| New | +$299K | 0.23% | 96 |
|
Other funds holding ABBV
Westhampton Capital's ABBV Position: Q2 2026 in Review
Westhampton Capital reduced its AbbVie (ABBV) stake by 0.35% in Q2 2026, selling an estimated $7.32K and leaving 9,800 shares worth $2.47M. The position accounts for 1.02% of the portfolio, ranked #27.
Westhampton Capital first reported a position in ABBV in Q2 2019 and has held it in 29 quarters since. 4,218 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Westhampton Capital held 9,800 shares of AbbVie worth $2.47M as of Q2 2026.
- Westhampton Capital sold 34 AbbVie shares in Q2 2026, an estimated $7.32K.
- AbbVie made up 1.02% of Westhampton Capital's portfolio in Q2 2026, its #27 holding.
- Westhampton Capital first reported a position in AbbVie in Q2 2019 and has held it in 29 quarters since.
- 4,218 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Westhampton Capital's 13F filing for Q2 2026, filed 14 Jul 2026.